Cytodigm is advancing the future of genetic medicine through innovative, non-viral drug delivery technologies. Our proprietary lipid-based nanoparticle (LNP) platforms enable precise, efficient delivery of nucleic acid payloads — including gene editing tools, mRNA therapeutics, and in vivo CAR constructs — supporting therapies for autoimmune diseases, cancers, and more. By overcoming barriers such as tissue distribution, cell targeting, and redosability, we expand the therapeutic reach of genetic medicine.

Collaboration is at our core. By combining our next-generation LNPs with the cutting-edge biology of our biopharma partners, we accelerate the development of cell, gene, and immune-based therapies while driving our own therapeutic pipeline toward clinical proof-of-concept.

Enabling Today. Transforming Tomorrow.

Cytodigm

This department focuses on scientific research and innovation to advance product development and technology.

Cytodigm

Org chart

Teams

Research and Development

Offices